EASD 2025 Highlights Podcast

Content sponsored by Eli Lilly (Suisse) SA

Diabetes Podcasts > EASD 2024 Highlights Podcast

Welcome to the EASD 2025 Highlights Podcast Series

The 2025 Annual Meeting of the European Association for the Study of Diabetes (EASD) took place this September in Vienna, Austria.

We’re excited to invite you to tune in to our podcast series, where three leading Swiss experts in diabetes and obesity treatment share their key takeaways and insights from the congress.

Overview

Episodes

Episode 1

Shaping future health: The role of screening and management of diabetes and obesity in women and children

Chapter 1 What are the benefits, harms, and available methods for type 1 diabetes screening?1
Chapter 2 Who should we screen, at what age, and how often?1
Chapter 3 Where should screening take place and how do we effectively communicate the results?1
Chapter 4 Obesity +/- diabetes “peri”-pregnancy – what to focus on2

Episode 2

Considering muscle in weight-loss efforts – preserving the balance

Chapter 1 Mechanisms preserving muscle mass3
Chapter 2 Healthy weight-loss with exercise and GLP-1 receptor agonist3
Chapter 3 Incretin-Associated Sarcopenia: Does It Matter Which Drug We Use?4
Chapter 4 Whole body imaging after obesity surgery or diet induced weight loss3

Episode 3

Incretins and cardiovascular protection – lessons from the latest CVOTs

Chapter 1 The cardiovascular outcomes in participants on tirzepatide versus dulaglutide of the SURPASS-CVOT5
Chapter 2 The glycaemic control and metabolic changes in participants on tirzepatide versus dulaglutide of the SURPASS-CVOT5

Chapter 3

Commentary

References:

  1. The emerging consensus for population level screening to detect early stage type 1 diabetes. Presented at EASO 2025, Sept 14-18; 10 SOl.
  2. EASO·EASO Joint Symposium: Obesity +/· diabetes “peri”·pregnancy-what to focus on. Presented at EASO 2025, Sept 14-18; 10 S09.
  3. Losing weight: Can the balance be preserved? Presented at EASO 2025, Sept 14· 18; 10 S04.
  4. lncretin-Associated Sarcopenia: Ooes lt Matter Which Orug We Use? Presented at EASO 2025, Sept 14-18; IS SP08.
  5. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT. Present ed at EASD 2025, Sept 14-18; 10 S18a.
  6. Tirzepatide www.swissmedicinfo.ch.

Health Care Professionals can request the references from the company at any time

This page is supported by:

Logo

Eli Lilly (Suisse) SA

Ch. des Coquelicots 16
1214 Vernier, Geneva

The content of this page is intended for Swiss physicians.

For further information on our Lilly products and therapeutic areas, please contact our Medical Information:
Service hours: Monday-Friday, 8:30-15:00 hrs
Phone: +41 44 654 57 52
E-Mail: ch_medinfo@lilly.com

PP-LD-CH-0613/10.2025